Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer

INTRODUCTION: Despite the impressive clinical response rate of osimertinib, a third-generation EGFR-TKI, as a frontline treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC) or as a salvage therapy for patients with T790M mutation, resistance to osimertinib is common in the clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ziying, Wang, Qiwei, Jiang, Tao, Wang, Weihua, Zhao, Jean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933873/
https://www.ncbi.nlm.nih.gov/pubmed/36817465
http://dx.doi.org/10.3389/fimmu.2023.1077203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933873/
https://www.ncbi.nlm.nih.gov/pubmed/36817465
http://dx.doi.org/10.3389/fimmu.2023.1077203

Ejemplares similares